Daré Bioscience Announces Funding Award Notice Of $2M From National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development to Support DARE-PTB1 Phase 1 Human Study
Portfolio Pulse from Benzinga Newsdesk
Daré Bioscience has received a $2M funding award from the National Institutes of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development. This award will support the Phase 1 human study of DARE-PTB1, a product in development by Daré Bioscience.
December 13, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Daré Bioscience has been awarded $2M by the NIH to support its Phase 1 study of DARE-PTB1, which could positively impact the company's research progress and financial stability.
The $2M funding award from the NIH is a significant financial boost for Daré Bioscience, directly supporting the development of DARE-PTB1. This influx of non-dilutive funding can help advance the product's clinical trials without impacting the company's equity, which is likely to be viewed positively by investors. The news directly pertains to Daré Bioscience and is critical for investors as it affects the company's research capabilities and financial health.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100